PAVmed (PAVmed) 3-Year Revenue Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is PAVmed 3-Year Revenue Growth Rate?

PAVmed's Revenue per Share for the three months ended in Mar. 2024 was $0.12.

During the past 12 months, PAVmed's average Revenue per Share Growth Rate was 277.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of PAVmed's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, PAVmed's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PAVmed's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where PAVmed's 3-Year Revenue Growth Rate falls into.

PAVmed 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

PAVmed (NAS:PAVM) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

PAVmed 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of PAVmed's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

PAVmed (PAVmed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PAVmed Inc (NAS:PAVM) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Madison Avenue, 25th Floor, New York, NY, USA, 10017

Website

http://www.pavmed.com

PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard and the Veris Cancer Care Platform.

Executives

Michael J Glennon	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Michael Adam Gordon	officer: General Counsel	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil	officer: Chief Operating Officer	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
James L Cox	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Debra White	director	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Ronald M Sparks	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Brian J. Deguzman	officer: Chief Medical Officer	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Dennis M Mcgrath	officer: President & CFO	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Lishan Aklog	director, 10 percent owner, officer: Chairman and CEO	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Joan B Harvey	director	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Timothy E Baxter	director	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Matthew Sirovich	10 percent owner	C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123
Ira Scott Greenspan	director	888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Joshua R Lamstein	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170